Dotatate gallium Ga-68

Generic Name
Dotatate gallium Ga-68
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C65H87GaN14O19S2
CAS Number
1027785-90-5
Unique Ingredient Identifier
9L17Y0H71P
Background

Dotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope. Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors. Dotatate gallium (Ga-68) explotes its ab...

Indication

Dotatate gallium 68 is one of the most prominent radiopharmaceuticals used in imaging with positron emission tomography. It binds to the somatostatin-2 receptor which is usually overexpressed in many neuroendocrine tumors in both adult and pediatric patients. The neuroendocrine tumors are bening or malignant tumors produced in the hormone producing cells of ...

Associated Conditions
Neuroendocrine Tumors
Associated Therapies
-
Clinical Trials
Related News

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Phase 3
Not yet recruiting
Conditions
Breast Cancer Metastatic
Interventions
Drug: 68Ga-DOTATOC
First Posted Date
2024-09-25
Last Posted Date
2024-09-25
Lead Sponsor
University Hospital, Grenoble
Target Recruit Count
25
Registration Number
NCT06611891
Locations
🇫🇷

CHU Grenoble Alpes, Grenoble, France

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

First Posted Date
2024-06-28
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT06479811
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

First Posted Date
2024-05-24
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT06427798
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Phase 3
Not yet recruiting
Conditions
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Drug: 68Ga-DOTATOC
First Posted Date
2023-10-19
Last Posted Date
2023-10-19
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
66
Registration Number
NCT06091748

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

First Posted Date
2021-10-06
Last Posted Date
2024-03-01
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
150
Registration Number
NCT05069220
Locations
🇨🇳

Peking union medical college hospital, Beijing, Dongcheng, China

Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO

First Posted Date
2020-12-30
Last Posted Date
2021-01-05
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
50
Registration Number
NCT04689893
Locations
🇨🇳

Peking union medical college hospital, Beijing, Dongcheng, China

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

First Posted Date
2020-10-30
Last Posted Date
2024-10-28
Lead Sponsor
Stanford University
Target Recruit Count
10
Registration Number
NCT04609592
Locations
🇺🇸

Stanford Cancer Institute Palo Alto, Stanford, California, United States

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

First Posted Date
2019-08-28
Last Posted Date
2024-11-28
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
30
Registration Number
NCT04069299
Locations
🇺🇸

H Lee Moffitt Cancer & Research Institute, Tampa, Florida, United States

68Ga-DOTATATE PET/CT in Neuroendocrine Tumor

Early Phase 1
Conditions
Neuroendocrine Tumors
Interventions
Drug: 68Ga-DOTATATE
First Posted Date
2019-08-01
Last Posted Date
2019-08-01
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
100
Registration Number
NCT04041882
Locations
🇨🇳

Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science, Beijing, China

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Phase 3
Completed
Conditions
Neuroendocrine Tumors
Interventions
Drug: 68Ga-DOTATOC
First Posted Date
2017-05-02
Last Posted Date
2023-05-09
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
11
Registration Number
NCT03136328
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy